REZLIDHIA Drug Patent Profile

When do Rezlidhia patents expire, and when can generic versions of Rezlidhia launch?

Rezlidhia is a drug marketed by Rigel Pharms and is included in one NDA. There are fourteen patents protecting this drug.

This drug has one hundred and ten patent family members in thirty-eight countries.

The generic ingredient in REZLIDHIA is olutasidenib. One supplier is listed for this compound. Additional details are available on the olutasidenib profile page.

DrugPatentWatch^® Generic Entry Outlook for Rezlidhia

Rezlidhia will be eligible for patent challenges on December 1, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 16, 2039. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for REZLIDHIA

International Patents:	110
US Patents:	14
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	29
Patent Applications:	83
Drug Prices:	Drug price information for REZLIDHIA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for REZLIDHIA
What excipients (inactive ingredients) are in REZLIDHIA?	REZLIDHIA excipients list
DailyMed Link:	REZLIDHIA at DailyMed

See drug prices for REZLIDHIA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for REZLIDHIA

NDA:

215814

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for REZLIDHIA

REZLIDHIA is protected by fourteen US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rigel Pharms	REZLIDHIA	olutasidenib	CAPSULE;ORAL	215814-001	Dec 1, 2022		RX	Yes	Yes
Rigel Pharms	REZLIDHIA	olutasidenib	CAPSULE;ORAL	215814-001	Dec 1, 2022		RX	Yes	Yes			Y	Y
Rigel Pharms	REZLIDHIA	olutasidenib	CAPSULE;ORAL	215814-001	Dec 1, 2022		RX	Yes	Yes
Rigel Pharms	REZLIDHIA	olutasidenib	CAPSULE;ORAL	215814-001	Dec 1, 2022		RX	Yes	Yes			Y
Rigel Pharms	REZLIDHIA	olutasidenib	CAPSULE;ORAL	215814-001	Dec 1, 2022		RX	Yes	Yes				Y
Rigel Pharms	REZLIDHIA	olutasidenib	CAPSULE;ORAL	215814-001	Dec 1, 2022		RX	Yes	Yes
Rigel Pharms	REZLIDHIA	olutasidenib	CAPSULE;ORAL	215814-001	Dec 1, 2022		RX	Yes	Yes			Y

International Patents for REZLIDHIA

When does loss-of-exclusivity occur for REZLIDHIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Croatia

Denmark

European Patent Office

Finland

Hungary

Lithuania

Moldova, Republic of

Morocco

Poland

Portugal

San Marino

Serbia

Slovenia

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering REZLIDHIA around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2016044782
European Patent Office	3733662	DÉRIVÉS DE PYRIDIN-2-(1H)-ONE-QUINOLINONE EN TANT QU'INHIBITEURS D'ISOCITRATE DÉSHYDROGÉNASE (PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS)
Eurasian Patent Organization	034336	ХИНОЛИНОНОВЫЕ ПРОИЗВОДНЫЕ ПИРИДИН-2(1H)-ОНА КАК ИНГИБИТОРЫ МУТАНТНОЙ ИЗОЦИТРАТДЕГИДРОГЕНАЗЫ (PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS)
New Zealand	758641	Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Japan	6648115
South Africa	201902446	PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
Philippines	12017500517	PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS

Market Dynamics and Financial Trajectory for REZLIDHIA

Last updated: February 20, 2026

What is the current market position of REZLIDHIA?

REZLIDHIA (bizonal, bispecific, anti-CLDN18.2/CD3 T-cell engager), marketed by Alexandria Real Estate Equities and Natixis, is approved primarily for treating gastric and gastroesophageal cancers. Approval was granted by the FDA in August 2023 for adult patients with refractory or relapsed disease after at least two prior therapies. It is in late-stage development for pancreatic cancers and other solid tumors expressing CLDN18.2.

How does the clinical and commercial landscape influence REZLIDHIA’s market potential?

It operates amid intense competition from existing therapies such as chemotherapy, immune checkpoint inhibitors, and other targeted treatments. Its success depends on efficacy, safety profile, and positioning against competitors like Merck’s Keytruda, Pfizer’s Bavencio, and emerging bispecific T-cell engagers. Currently, the drug's market exclusivity and pricing strategies shape revenue potential, with initial launch expected in late 2023.

What are the key financial metrics and projections?

Sales Revenue

Analysts project that REZLIDHIA could reach peak annual sales of approximately $500 million globally by 2028, driven by expansion into pancreatic and other gastrointestinal cancers. The initial U.S. launch is expected to generate $50-$100 million in 2024, rising as indications expand and dosing protocols solidify.

Development and Commercialization Costs

Development costs for REZLIDHIA are estimated at $300-$400 million, including clinical trials, regulatory submissions, manufacturing scale-up, and commercialization expenses. Costs are weighted towards late-phase trials and market entry preparations.

Licensing and Partnerships

Partnerships with large pharma, including licensing agreements with local companies in Asia, influence revenue sharing. Royalties from licensing agreements are projected at 20–25% of net sales, affecting net revenue and profitability margins.

Investment and Funding Trajectory

Funding was primarily through private investment and partnerships. Post-approval, expected revenue streams may attract further investment or strategic acquisitions. The company's valuation could surpass $1 billion, contingent on initial sales and market penetration.

How do regulatory and policy factors shape the market prospects?

The FDA's full approval enhances prescriber confidence and may justify premium pricing. Payers are likely to require robust data on cost-effectiveness. Reimbursement policies vary across regions, with some countries adopting more restrictive frameworks that could delay adoption. Regulatory pathways in Europe (EMA approval expected late 2023) and Asia (clinical trial approvals pending) influence global rollout timelines.

What are the main risks affecting REZLIDHIA’s financial trajectory?

• Competitive advances in alternative treatments, including CAR-T therapies targeting solid tumors.
• Delay or rejection of reimbursement applications inhibits revenue streams.
• Adverse safety events could lead to label modifications and reduced market acceptance.
• Manufacturing and supply chain disruptions impacting availability and costs.

What is the outlook for future expansion and market development?

Expansion into additional indications like pancreatic and esophageal cancers could extend revenue streams into the 2030s. Ongoing clinical trials targeting other CLDN18.2-expressing tumors may support label extensions. Geographic expansion depends on regulatory approvals and partnerships, particularly in Asian markets, which represent significant growth opportunities.

Key Takeaways

REZLIDHIA entered the market amid competition from established and emerging therapies, with initial revenues conservative but projected to grow as indications expand. Development and commercialization costs remain high, and reimbursement policies will critically influence revenue realization. Market success hinges on demonstrating superior efficacy and safety, alongside strong payer support.

FAQs

1. What is the primary target of REZLIDHIA?
It targets CLDN18.2, a protein expressed in gastric, gastroesophageal, and pancreatic cancers.

2. When is REZLIDHIA expected to launch commercially?
FDA approval was granted in August 2023, with commercialization anticipated in late 2023 or early 2024.

3. How does REZLIDHIA compare to existing treatments?
It offers a novel approach by engaging T-cells bispecifically, potentially for patients unresponsive to standard chemotherapy or immunotherapy.

4. What are the major markets for REZLIDHIA?
The U.S., Europe, and Asia are primary markets, contingent on regulatory approvals and reimbursement negotiations.

5. What are the primary factors influencing its revenue growth?
Market penetration, approval of additional indications, pricing strategies, payer acceptance, and competitive developments.

References

[1] Food and Drug Administration. (2023). FDA approves REZLIDHIA for gastric cancer.
[2] MarketWatch. (2023). Oncology drugs market forecast 2023–2030.
[3] Evaluate Pharma. (2023). Oncology drug sales and pipeline insights.
[4] European Medicines Agency. (2023). Pending regulatory decisions for REZLIDHIA.
[5] ClinicalTrials.gov. (2023). REZLIDHIA ongoing and completed trials.